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followed. Results: 24.32% of patients with hematuria were
found to have a bladder cancer; 20.78% had a urinary stone;
1.18% had prostate cancer; 1.18% had a renal cell carcinoma;
0.39 had a urachus neoplasm. The mean age was 68.6 yrs.
5.8% of the patients (24.2% on patients with TCC of the
bladder) had a G3 disease. The mean time from admission to
the HOSC until the operation day, in case of TCC of the
bladder, was 11.1 days. The mean access time to HOSC since
the event of haematuria was 3.88 days. The patient average
satisfaction level, for those referred to the HOSC, was 4.5 (on
a scale from 1 to 5). Conclusion: The Italian experience of the
One Stop Clinic confirms a high rate of bladder cancer
detection. Furthermore, a high rate of non-malignant
conditions was detected, stressing the importance of the
HOSC not only as a cancer clinic but as a complete general
urological clinic. We report a shorter waiting time to
operation, especially for bladder TCC G3 patients. It should
be a mission of all urologists who manage this disease to
ensure that timely and evidence-based treatment is available
to all patients; this should include education of referring
providers within their community about bladder cancer
awareness and the importance of timely referral for evaluation
of haematuria. 
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Background: The reduction of the number of negative prostate
biopsies in patients with elevated serum PSA represents a
major challenge. Several angiogenetic biomarkers are involved
in carcinogenesis and cancer progression. The aim of our
preliminary study was to investigate if their serum levels might
be related to prostate cancer detection. Patients and Methods:
Angiopoietin 2, Follistatin, G-CSF, HGF, IL-8, Leptin, PDGF-
BB, PECAM-1, VEGF, PTH were the selected biomarkers for
our research. They were measured by BioPlex immunoassay.
As a preliminary step, consecutive unselected patients
undergoing prostate biopsy for palpable prostate nodule and/or
elevated PSA levels were entered. A 12-core transrectal biopsy
was planned. The serum levels of the above mentioned
biomarkers were related with the histological result of the
biopsy. ROC curve analysis was exploited to test the
diagnostic accuracy of each biomarker by AUC calculation. A
potential cut-off level was computed for each biomarker.
Results: Thirty-five consecutive patients were entered in this
preliminary study. The median PSA was 6.3 ng/ml (mean:
19.4, range 0.41-364). An altered prostate was found at digital
rectal examination in 13 (37%) patients. Transrectal ultrasound
gave a median prostate volume of 44.5 cc (mean 48.7; range
15-105cc). Seven patients (20%) had a previous negative
biopsy and 5 were receiving dutasteride or finasteride. A
median number of 12 biopsy cores was obtained (mean: 12
range 4-24). Prostate cancer was detected in 21 (60%) men.
ASAP and PIN were detected in 2 more patients respectively.
Among the 9 considered angiogenetic biomarkers, only leptin
preliminarily shows an interesting diagnostic accuracy with an
AUC of 0,714 (Table 1). At a cut-off value of 2166 pg/ml,
leptin demonstrates a sensitivity of 74% and a specificity of
75% with a positive predictive value of 85%. Conclusion:
Only leptin, among the 9 studied biomarkers, showed
promising diagnostic accuracy for the detection of prostate
cancer, suggesting the usefulness of further research. 
Table I. ROC curve analysis (AUC).
Angiogenetic biomarker AUC
Angiopoietin_2 0.511
Follistatin 0.676
G-CSF 0.658
HGF 0.636
IL-8 0.524
Leptin 0.714
PDGF-BB 0.638
PECAM-1 0.596
VEGF 0.589
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Introduction: Aim of this study was to report the outcomes of
a single institution study on 98 pts with clinically locally
advanced prostate cancer (PCa) and prostate specific antigen
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